Abstract:Advanced melanoma has seen dramatic changes in standard of care in the last years and many novel targeted small molecules and immune checkpoint inhibitors are in development. More than 200 clinical trials are currently ongoing for metastatic melanoma. Thus, accurate pre-clinical models to predict clinical responses are urgently needed. We have established a large bank of live tumor tissue (n=500) with more than 300 models expanded as PDX. Melanoma tumor tissue is uniquely suited to establish patient-derived xenograft (PDX) models, since only one tumor cell can initiate tumor growth. Thus, our success rate is at 90% using NSG mice and matrigel for s.c. implantation of minced tissue chunks. We have opted for such a large number of models due to the genomic and clinical heterogeneity of melanoma based on available TCGA data. Although almost half of all melanomas harbor BRAF V600 hotspot mutations, followed in frequency by NRAS and NF1 mutations, many driver mutations are only found in a small subset and many mutations are occurring concurrently in various confirmations. We used a custom targeted capture of 108 genes previously implicated in melanoma, and performed massively parallel sequencing on currently 200 PDX. Samples were then clustered into groups based on deleterious mutations which were detected in all but a very small subset of samples. The biological relevance of these multiple genomic subsets was then tested against latency, growth rate, and spontaneous metastasis in PDX. Further, clinical information such as age, gender, history, and response to therapies provided additional parameters to classify this collection into meaningful subgroups. In conclusion, this collection of melanoma PDX recapitulates the breadth of advanced melanoma in the clinic and therefore a comprehensive resource for precision medicine testing in an increasingly scattered therapy landscape. Citation Format: Clemens Krepler, Katrin Sproesser, Marilda Beqiri, Min Xiao, Patricia Brafford, Wei Xu, Bradley Garman, Jennifer Wargo, Michael A. Davies, Dennie T. Frederick, Keith T. Flaherty, David Hoon, Joseph J. Bennett, Michael Guarino, Nicholas J. Petrelli, David Elder, Xiaowei Xu, Giorgos Karakousis, KATHERINE L. NATHANSON, Lynn Schuchter, Meenhard Herlyn. A comprehensive collection of patient derived xenografts of human melanoma with clinical, genomic, and biological characterization. [abstract]. In: Proceedings of the AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; Feb 11-14, 2016; New Orleans, LA. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(16_Suppl):Abstract nr A01.

Melanoma models for the next generation of therapies

A Preclinical Model of Patient-Derived Cerebrospinal Fluid Circulating Tumor Cells for Experimental Therapeutics in Leptomeningeal Disease from Melanoma.

Pre-clinical modeling of cutaneous melanoma

Patient-derived melanoma models

Interaction of Molecular Alterations with Immune Response in Melanoma

Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy

Bridging the gap between testing and clinics exploring alternative pre-clinical models in melanoma research

Abstract A01: A comprehensive collection of patient derived xenografts of human melanoma with clinical, genomic, and biological characterization

Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance

A preclinical model of cutaneous melanoma based on reconstructed human epidermis

A Melanoma Patient-Derived Xenograft Model

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

The Landscape of Gain and Loss of Function Mutations in Melanoma

Roadmap for new opportunities in melanoma research

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models

Stepwise-edited, human melanoma models reveal mutations’ effect on tumor and microenvironment

Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics

Abstract PR02: Humanized Mouse Melanoma Model Using Patient-Derived Xenografts

Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs’ Revolution for Immunotherapy

A Reconstructed Human Melanoma-in-Skin Model to Study Immune Modulatory and Angiogenic Mechanisms Facilitating Initial Melanoma Growth and Invasion

Experimental models for primary melanoma